Tag: new cancer drugsSort
Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug
Jim Boeheim and Cellceutix (CTIX) Team to Fight Cancer
Clinical trials should be starting at Harvard's Dana-Farber Cancer Center in the next two months as Cellceutix looks to validate their laboratory research on Kevetrin, their novel drug in development for the treatment of drug resistant cancers. Yesterday, it was disclosed that Syracuse basketball icon Jim Boeheim has come on board the Cellceutix team in the fight against cancer.
Cellceutix Featured on Front Page of Boston Business Journal
Cellceutix continues to gain industry attention by both investors, big pharma and publications. Their Chief Executive Officer was featured on the front page of Friday's Boston Business Journal. As the clinical trials for Kevetrin should be starting in a couple months at Dana-Farber, attention should continue to increase.
Cellceutix (CTIX) Makes Another Breakthrough in Cancer Research
Cellceutix Corporation (OTCBB:CTIX) has regularly reported significant breakthroughs in cancer research through studies of Kevetrin, the company’s novel cancer drug in development. Amazing data has been collected by Cellceutix researchers testing Kevetrin against many cancer lines, including head & neck, prostate, lung, colon, pancreatic and leukemia.
Cellceutix Files Investigational New Drug Application with FDA for Novel Cancer Drug
With the hubbub around p53 as a potential breakthrough in cancer research, it is interesting to note that Cellceutix Corporation (OTCBB:CTIX) has submitted its Investigational New Drug application to the FDA. The news was posted on their website after the closing bell on Friday and released nationally this morning.